The Interleukin 17F pipeline drugs market research report outlays comprehensive information on the Interleukin 17F targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 17F pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Interleukin 17F - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers products from therapy areas such as Immunology, Dermatology, Musculoskeletal Disorders, and Undisclosed which include the indications Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Hidradenitis Suppurativa, Atopic Dermatitis (Atopic Eczema), Ankylosing Spondylitis (Bekhterev’s Disease), Psoriatic Arthritis, and Unspecified. It also reviews key players involved in Interleukin 17F targeted therapeutics development with respective active and dormant or discontinued products.

The Interleukin 17F pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical, and Discovery stages are 1, 3, 1, 4, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Interleukin 17F overview

Interleukin 17F (IL17F) cytokine is expressed by activated T cells, and has been shown to stimulate the production of several other cytokines, including IL6, IL8, and CSF2/GM-CSF. IL17F homodimer can signal via IL17RC homodimeric receptor complex, triggering downstream activation of TRAF6 and NF-kappa-B signaling pathway. IL17F is an effector cytokine of the innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity.

For a complete picture of Interleukin 17F’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.